论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)组织中血管内皮生长因子A(VEGF-A)和Survivin的表达情况及临床意义。方法:采用免疫组织化学SP法对48例术后NSCLC碏块进行免疫组织化学染色,检测VEGF-A、Survivin的表达水平,并分析NSCLC组织中VEGF-A、Survivin的表达水平与NSCLC的组织分型、淋巴结转移、临床病理分期的关系。结果:VEGF-A在NSCLC组织中的阳性表达率(68.75%)明显高于正常肺组织(6.25%),并与淋巴结转移有关(χ2=11.95,P<0.05)。Survivin在NSCLC组织中的阳性表达率明显增加(54.17%),并且与有无淋巴结转移(χ2=8.08,P<0.05)及TNM分期(χ2=5.19,P<0.05)有关。两者在不同病理类型NSCLC组织中的表达差异无统计学意义。结论:VEGF-A、Survivin的表达可作为临床评估NSCLC的进展、转移、预后及治疗的重要检测指标。
Objective: To investigate the expression of vascular endothelial growth factor A (VEGF-A) and Survivin in non-small cell lung cancer (NSCLC) and its clinical significance. Methods: Immunohistochemical SP method was used to detect the expression of VEGF-A and Survivin in 48 cases of postoperative NSCLC. The expressions of VEGF-A and Survivin in NSCLC were compared with those in NSCLC Type, lymph node metastasis, clinical stage of the relationship. Results: The positive expression rate of VEGF-A in NSCLC tissues was significantly higher than that in normal lung tissues (6.25%) (68.75%), which was correlated with lymph node metastasis (χ2 = 11.95, P <0.05). The positive expression rate of Survivin in NSCLC tissues was significantly increased (54.17%), with or without lymph node metastasis (χ2 = 8.08, P <0.05) and TNM stage (χ2 = 5.19, P <0.05). There was no significant difference in the expression of the two in different pathological types of NSCLC. Conclusion: The expression of VEGF-A and Survivin can be used as important indexes in the clinical evaluation of the progression, metastasis, prognosis and treatment of NSCLC.